hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06328387 id: SYSKY-2024-064-03 briefTitle: HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer overallStatus: RECRUITING date: 2024-01-29 date: 2026-02-01 date: 2026-03-01 date: 2024-03-25 date: 2024-03-25 name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University class: OTHER briefSummary: Advanced breast cancer is a special subtype of human breast cancer. Conventional guidelines recommend chemotherapy combined with other adjuvant therapies for this subtype of patients. However, the choice of treatment for these patients after treatment progress is a research hotspot in this field. Trastuzumab Deruxtecan (T-DXd) and Sacituzumab Govitecan (SG) are new ADC drugs targeting HER2 or TROP-2 with high efficacy and low toxicity after the progress of first-line treatment. The autophagy agents hydroxychloroquine or chloroquine has become the only FDA (Food and Drug Administration) approved autophagy inhibitor, and hydroxychloroquine and antibody-drug conjugate(ADC) may have synergistic effects based on the previous work results of our research group.
To this end, we intend to conduct a prospective,multi-center, phase I/II clinical trial to evaluate the efficacy and safety of T-DXd or SG in combination with HCQ in patients with advacned breast cancer. conditions: Advanced Breast Cancer conditions: Metastatic Breast Cancer studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The research model consists of four arms：
4. arm D: HCQ+T-DXd. primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: Hydroxychloroquine name: Sacituzumab Govitecan name: Trastuzumab Deruxtecan measure: Dose Limiting Toxicity, DLT measure: Adverse event, AE measure: Objective Response Rate, ORR measure: Progression-Free Survival, PFS measure: Overall Survival, OS measure: Clinical Benefit Rate, CBR measure: Disease Control Rate, DCR measure: The rate of adverse events measure: Quality of life scale score, QoL measure: Exploration of biomarkers sex: FEMALE minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-sen Memorial Hospital, Sun Yat-sen University status: RECRUITING city: Guangzhou state: Guangdong zip: 510120 country: China name: Jianli J Zhao, doctorate role: CONTACT phone: 15920589334 email: zhaojli5@mail.sysu.edu.cn lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06328374 id: 240420 briefTitle: Voice and Swallowing Disorders in Adults With and Without Alzheimer's Disease overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-03 date: 2026-12 date: 2024-03-25 date: 2024-03-26 name: Vanderbilt University Medical Center class: OTHER briefSummary: This research study is investigating whether people with Alzheimer's disease experience more changes to voice and swallowing than their healthy age-matched peers. The prevalence of swallowing impairments in moderate-severe Alzheimer's Disease is high (85-93%) and voice is also often negatively impacted by Alzheimer's disease. The overall objective of this study is to evaluate the voice and swallowing function of adults with and without Alzheimer's disease. The investigators will also be involving the primary caregivers of individuals with Alzheimer's that are enrolled in the study to better understand the impact of voice and swallowing impairments on the primary caregivers of those with Alzheimer's Disease.
Caregivers of individuals with Alzheimer's disease will also complete questionnaires. conditions: Alzheimer Disease conditions: Caregiver Burden conditions: Healthy Aging conditions: Dysphonia conditions: Dysphagia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 120 type: ESTIMATED measure: Swallowing safety measure: Voluntary cough peak expiratory flow measure: Vocal fold bowing index measure: Swallowing and Eating Related Fatigue Questionnaire (SERF) measure: Swallowing Related Quality of Life Questionnaire (SWAL-QOL) measure: Voice Handicap Index (VHI) measure: Aging Voice Index (AVI) measure: Grip Strength measure: Tongue strength measure: Clinical frailty scale measure: Caregiver Analysis of Reported Experiences with Swallowing Disorders (CARES) Questionnaire measure: Caregiver Self-Assessment Questionnaire sex: ALL minimumAge: 60 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06328361 id: R24008 briefTitle: Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer acronym: NORPPA-1 overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2028-12-31 date: 2032-12-31 date: 2024-03-25 date: 2024-03-25 name: Tampere University Hospital class: OTHER name: Tampere University name: Helsinki University Central Hospital name: Turku University Hospital name: Kuopio University Hospital name: Oulu University Hospital name: Jyväskylä Central Hospital name: Seinajoki Central Hospital name: Satakunta Central Hospital name: North Karelia Central Hospital name: Tartu University Hospital name: East Tallinn Central Hospital name: West Tallinn Central Hospital name: North Estonia Medical Centre briefSummary: The goal of this one-arm clinical trial is to implement and study the oncological outcomes of nonoperative management of rectal cancer having complete clinical response to neoadjuvant therapy. The main questions to answer are
* what is the local regrowth rate conditions: Rectal Cancer conditions: Rectal Adenocarcinoma studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 200 type: ESTIMATED name: Nonoperative surveillance measure: Disease-free survival measure: Overall survival measure: TME-free survival measure: ctDNA-free survival measure: Post local regrowth disease-free survival measure: Post local regrowth overall survival measure: Local regrowth-free survival measure: Local recurrence-free survival measure: Distant metastases-free survival measure: Disease-free survival measure: Salvage rate after local regrowth measure: Quality of life score measure: Complication rates sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: East Tallinn Central Hospital city: Tallinn country: Estonia lat: 59.43696 lon: 24.75353 facility: North Estonia Medical Centre city: Tallin country: Estonia name: Indrek Seire, MD, PhD role: CONTACT email: indrek.seire@ut.ee lat: 59.43696 lon: 24.75353 facility: West Tallinn Central Hospital city: Tallin country: Estonia name: Kaur Liivak, MD, PhD role: CONTACT email: kaur.liivak@keskhaigla.ee lat: 59.43696 lon: 24.75353 facility: Tartu University Hospital city: Tartu country: Estonia name: Jaan Soplepman, MD, PhD role: CONTACT email: jaan.soplepmann@kliinikum.ee lat: 58.38062 lon: 26.72509 facility: Helsinki University Central Hospital city: Helsinki zip: 00290 country: Finland name: Anna H Lepistö, MD, PhD role: CONTACT email: anna.lepisto@hus.fi lat: 60.16952 lon: 24.93545 facility: North Karelia Central Hospital city: Joensuu country: Finland name: Markku Matikainen, MD, PhD role: CONTACT email: markku.matikainen@siunsote.fi, lat: 62.60118 lon: 29.76316 facility: Jyväskylä Central Hospital city: Jyväskylä country: Finland name: Kyösti Tahkola, MD, PhD role: CONTACT email: kyosti.tahkola@hyvaks.fi lat: 62.24147 lon: 25.72088 facility: Kuopio University Hospital city: Kuopio country: Finland name: Anne Fageström, MD, PhD role: CONTACT email: anne.fagerstrom@pshyvinvointialue.fi lat: 62.89238 lon: 27.67703 facility: Oulu University Hospital city: Oulu country: Finland name: Karoliina Paarmio, MD, PhD role: CONTACT email: karoliina.paarnio@pohde.fi lat: 65.01236 lon: 25.46816 facility: Satakunta Central Hospital city: Pori country: Finland name: Jyrki Haikonen, MD, PhD role: CONTACT email: jyrki.haikonen@sata.fi lat: 61.48333 lon: 21.78333 facility: Seinajoki Central Hospital city: Seinäjoki country: Finland lat: 62.79446 lon: 22.82822 facility: Tampere University Hospital city: Tampere zip: 33400 country: Finland name: Toni T Seppälä, MD, PhD role: CONTACT phone: +358444722846 email: toni.seppala@tuni.fi lat: 61.49911 lon: 23.78712 facility: Turku University Hospital city: Turku country: Finland name: Pirita Varpe, MD, PhD role: CONTACT email: Pirita.Varpe@tyks.fi lat: 60.45148 lon: 22.26869 hasResults: False
nctId: NCT06328348 id: SW010 briefTitle: Assessing the Synergistic Effects of Black Cohosh, Soy Isoflavones, and SDG Lignans (Soloways TM) on Menopausal Symptoms overallStatus: COMPLETED date: 2023-07-18 date: 2023-11-30 date: 2023-12-30 date: 2024-03-25 date: 2024-03-25 name: S.LAB (SOLOWAYS) class: OTHER name: Center of New Medical Technologies briefSummary: This clinical trial aimed to evaluate the effectiveness of a combination of Black Cohosh, Soy Isoflavones, and SDG Lignans compared to a placebo in reducing menopausal symptoms in postmenopausal women aged 45-60 years. The study was meticulously designed to be a randomized, double-blind, parallel-group trial, ensuring rigorous scientific standards and participant confidentiality. It received ethical approval and adhered to the Declaration of Helsinki guidelines. Participants were carefully selected based on specific inclusion and exclusion criteria to maintain the study's integrity and relevance to the target population.
The trial involved 96 eligible women from the Center for New Medical Technologies registry in Novosibirsk, Russia, divided into two groups through a computer-generated random sequence. One group received the active supplements, while the other received a placebo, with both groups and researchers blinded to the assignments. The supplements and placebos were produced to be indistinguishable in appearance, with dosages designed to maximize absorption and efficacy while minimizing side effects. The primary endpoint was the change in Menopause Rating Scale (MRS) scores, with secondary outcomes focusing on adverse symptoms and key hormonal changes.
The study's design also included measures to ensure adherence and minimize bias, such as drug container returns and daily reminders. The involvement of S.Lab (Soloways) was limited to manufacturing the supplements, with the research conducted independently to avoid commercial influence. The sample size calculation indicated that 48 participants per group would provide adequate power to detect significant differences in menopausal symptom reduction, aiming for a high level of confidence and statistical power. conditions: Menopause Symptoms studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 96 type: ACTUAL name: supplementation name: placebo measure: Change in the Menopause Rating Scale (MRS) score measure: Follicle-Stimulating Hormone (FSH) change measure: Estradiol change measure: Number of any adverse events sex: FEMALE minimumAge: 45 Years maximumAge: 60 Years stdAges: ADULT facility: Center of New Medical Technologies city: Novosibirsk state: Novosibisk Region zip: 630090 country: Russian Federation lat: 55.0415 lon: 82.9346 hasResults: False
nctId: NCT06328335 id: Orthostatic Hypotension briefTitle: The Effect of Rehabilitation Training on Orthostatic Hypotension in Parkinson's Patients overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12 date: 2024-12 date: 2024-03-25 date: 2024-03-25 name: Copka Sonpashan class: OTHER_GOV briefSummary: The goal of this clinical trial is to explore raise-bed training Orthostatic Hypotension in Parkinson's Patients. The main question it aims to answer is:
Can raise-bed training improve Orthostatic Hypotension in Parkinson's Patients. Patients will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given raise-bed training. The study lasts 21 days for each patient. Researchers will compare Orthostatic Hypotension Questionnaire, Orthostatic Grading Scale, Composite Autonomic Symptom Scale 31 to see if raise-bed training can help improve the symptom conditions: Orthostatic Hypotension studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Comprehensive rehabilitation training name: Rise-bed Training measure: Composite Autonomic Symptom Scale 31 measure: Orthostatic Hypotension Questionnaire measure: Orthostatic Grading Scale sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06328322 id: Soh-Med-24-03-02MD briefTitle: Study of Percutaneous Coronary Intervention in Left Main Coronary Artery Disease in Patients With Acute Coronary Syndrome at Sohag University Hospitals overallStatus: RECRUITING date: 2024-04-01 date: 2025-04-01 date: 2025-04-01 date: 2024-03-25 date: 2024-03-25 name: Sohag University class: OTHER briefSummary: Acute coronary syndromes (ACS) encompass a spectrum of cardiovascular disorders characterized by the sudden onset of myocardial ischemia. They are primarily caused by atherosclerotic plaque rupture or erosion, leading to partial or complete occlusion of the coronary arteries. Among the various coronary arteries affected, left main coronary artery disease (LMCAD) is of particular concern due to its high anatomical significance and potential for adverse outcomes
The left main coronary artery (LMCA) is responsible for supplying a substantial portion of the left ventricular myocardium, including the interventricular septum and the anterior and lateral walls. Any obstruction or compromise in blood flow within this critical artery can have severe consequences, including myocardial infarction, heart failure, or even sudden cardiac death. The management of LMCAD associated with ACS represents a significant clinical challenge, necessitating prompt and optimal treatment strategies
Among the various coronary arteries affected by atherosclerosis, left main coronary artery disease (LMCAD) holds particular clinical significance due to its anatomical location and the vital role it plays in supplying a substantial portion of the left ventricular myocardium. The left main coronary artery (LMCA) typically bifurcates into the left anterior descending artery (LAD) and the left circumflex artery (LCX), which together provide blood supply to the majority of the left ventricle, including the interventricular septum and the anterior and lateral walls
The selection of an appropriate treatment strategy for LMCAD associated with ACS is a complex decision that requires careful consideration of multiple factors, including patient characteristics, coronary anatomy, severity of ischemia, and procedural expertise. The emergence of several clinical trials and observational studies exploring the efficacy and safety of different revascularization strategies has further complicated the decision-making process conditions: Left Main Coronary Artery Disease With Acute Coronary Syndrome studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 50 type: ESTIMATED name: Percutaneous Coronary Intervention in Left Main Artery Disease measure: major adverse cardiac events (MACE) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sohag university Hospital status: RECRUITING city: Sohag country: Egypt name: Magdy M Amin, professor role: CONTACT lat: 26.55695 lon: 31.69478 hasResults: False
nctId: NCT06328309 id: Myofascial Traumatic Brain briefTitle: Impact of v Release on Dysphagia in Patients With Traumatic Brain Injury overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2024-12 date: 2024-12 date: 2024-03-25 date: 2024-03-25 name: Copka Sonpashan class: OTHER_GOV briefSummary: The goal of this clinical trial is to explore Clinical Effect of Myofascial Release Therapy in Dysphagic Traumatic Brain injured Survivors. The main question it aims to answer is:
• Can Myofascial Release Therapy improve swallowing function in Traumatic Brain injured Survivors? Patients will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given Myofascial Release Therapy. The study lasts 21 days for each patient. Researchers will compare the Functional Oral Intake Scale, Penetration-Aspiration Scale, Swallowing Quality of Life to see if the Myofascial Release Therapy can help improve the situation. conditions: Traumatic Brain Injury studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Rehabilitation treatment name: Myofascial Release Therapy measure: Penetration-Aspiration Scale measure: Swallowing Quality of Life questionnaire measure: Patient health questionnaire-9 measure: Functional Oral Intake Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06328296 id: Myofascial Parkinson's Dysphag briefTitle: Impact of Myofascial Release on Dysphagia in Parkinson's Disease Patients overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12 date: 2024-12 date: 2024-03-25 date: 2024-03-25 name: Copka Sonpashan class: OTHER_GOV briefSummary: The goal of this clinical trial is to explore Clinical Effect of Myofascial Release Therapy in Dysphagic Parkinson's Patients. The main question it aims to answer is:
• Can Myofascial Release Therapy improve swallowing function in Parkinson's Patients? Patients will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given Myofascial Release Therapy. The study lasts 21 days for each patient. Researchers will compare the Functional Oral Intake Scale, Penetration-Aspiration Scale, Swallowing Quality of Life to see if the Myofascial Release Therapy can help improve the situation. conditions: Parkinson Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Rehabilitation treatment name: Myofascial Release Therapy measure: Penetration-Aspiration Scale measure: Swallowing Quality of Life questionnaire measure: patient health questionnaire-9 measure: Functional Oral Intake Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06328283 id: Soh-Med-24-02-01MD briefTitle: The Diagnostic Efficacy of Glutamine Synthetaseand BCLAF1in Early Diagosis of Hepatocellular Carcinoma in Cirrhotic Patients overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-03-01 date: 2026-03-01 date: 2024-03-25 date: 2024-03-25 name: Sohag University class: OTHER briefSummary: Hepatocellular carcinoma (HCC) is the most prominent kind of liver cancer, accounting for 85% of primary liver malignancies. It is a very aggressive tumor, having a terrible prognosis and poor survival rate HCC is ranked as the sixth most common type of cancer and the third leading cause of cancer-related mortalities world wide.
HCC incidences arise in complications associated with chronic liver disease like cirrhosis, endemic hepatitis B virus (HBV)/hepatitis C virus (HCV) infections, non alcoholic fatty liver disease (NAFLD), and alcohol-related liver disease (Torre, 2015). conditions: Hepatocellular Carcinoma studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 90 type: ESTIMATED name: measure of Glutamine synthetase and BCLFAF1 measure: glutamine synthetase sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Sohag university Hospital city: Sohag state: Sohagm country: Egypt name: Magdy M Amin, professor role: CONTACT lat: 26.55695 lon: 31.69478 hasResults: False
nctId: NCT06328270 id: 03.09.2019 / 2505 briefTitle: Comparison of the Therapeutic Effects of Intra-Articular Injection of Ozone and Corticosteroid in Knee Osteoarthritis overallStatus: COMPLETED date: 2020-09-01 date: 2022-01-30 date: 2022-03-30 date: 2024-03-25 date: 2024-03-25 name: Sisli Hamidiye Etfal Training and Research Hospital class: OTHER briefSummary: This clinical trial aimed to involve patients aged 40-85 years who had been experiencing knee pain for at least 6 months and had received a clinical diagnosis of knee osteoarthritis through radiologic imaging. The patients were randomly assigned to two groups. One group received a 3-week intra-articular injection of 15 mg/ml ozone, while the second group received a 1 ml intra-articular injection of betamethasone. All patients were evaluated before treatment, as well as 4 and 12 weeks after the first dose of treatment. The study evaluated treatment efficacy using the Visual Pain Score (VAS) and the Western Ontario and McMaster Universities Arthritis Index (WOMAC). conditions: Knee Osteoarthritis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 60 type: ACTUAL name: Ozone - oxygen Therapy name: Corticosteroid measure: Visual Pain Score measure: Western Ontario and McMaster Universities Arthritis Index measure: Visual Pain Score measure: Western Ontario and McMaster Universities Arthritis Index sex: ALL minimumAge: 40 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Health Sciences, Şişli Hamidiye Etfal Training and Research Hospital city: Istanbul country: Turkey lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06328257 id: Elderly Community Myofascial briefTitle: Impact of Myofascial Release on Preventing Dysphagia in the Elderly Community overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-08 date: 2024-08 date: 2024-03-25 date: 2024-03-25 name: Copka Sonpashan class: OTHER_GOV briefSummary: The goal of this clinical trial is to explore the impact of Myofascial Release Training on swallowing function and quality of life in community-dwelling elderly individuals (≥60 year old) with swallowing disorders. It primarily aims to address the effects of Myofascial Release Training on swallowing function and quality of life in community-dwelling elderly individuals with swallowing disorders. All participants are required to undergo a continuous three-week (21 days) Myofascial Release Training, with weekends off and training conducted only on weekdays. The training will be conducted two sessions per day, lasting 15-30 minutes each. conditions: Dysphagia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 300 type: ESTIMATED name: Myofascial Release Training measure: Swallowing-Related Quality of Life Questionnaire measure: Time consumed in eating measure: Functional Oral Intake Scale sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False